Catalent Appoints David McErlane as Biologics Segment Leader

2023-09-18

高管变更

SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that David McErlane has been named Group President of Catalent’s Biologics segment, effective September 25, 2023. Mr. McErlane joins Catalent from Lonza, where he served as senior vice president and business unit head for Lonza’s Bioscience business. Prior to joining Lonza, Mr. McErlane held several leadership positions at MilliporeSigma and BioReliance after beginning his career as an engineering manager at Zeneca. He holds a bachelor’s degree in electronic systems engineering from Glasgow Caledonian University. “David is a seasoned and highly successful business leader with a record of developing winning strategies that drive growth and create significant value,” said Alessandro Maselli, President and Chief Executive Officer of Catalent. “I am excited to work with David, who I am confident will make an immediate, positive impact on our Biologics business and help take Catalent to its next phase of growth.” Mr. McErlane will lead all of Catalent’s Biologics businesses and global service offerings – including development, drug substance manufacturing, drug product fill-and-finish, cell and gene therapy, and analytical services. About Catalent, Inc. Catalent, Inc. (NYSE: CTLT), is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,500 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply approximately 70 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of nearly 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $4.3 billion in revenue in its 2023 fiscal year. For more information, visit . More products. Better treatments. Reliably supplied.™ View source version on businesswire.com: Contacts Investor Contact: Paul Surdez (732) 537-6325 investors@catalent.com Media Contact: Bernie Clark +1 (732) 537-6400 media@catalent.com Source: Catalent, Inc. View this news release online at:

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构